Avapritinib Approval Status
FDA Approved: No
Generic name: avapritinib
Company: Blueprint Medicines Corporation
Treatment for: Gastrointestinal Stromal Tumor
Avapritinib (formerly known as BLU-285) is a potent and highly selective KIT and PDGFRα inhibitor in development for the treatment of PDGFRα Exon 18 mutant gastrointestinal stromal tumors (GIST) and fourth-line GIST.
Development Status and FDA Approval Process for avapritinib
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.